Fangzhou's AI-Powered Chronic Care Model Named to Fortune China's Best Designs 2026
核心洞察
Fangzhou Inc. (搜索)'s "AI + Chronic Care" platform, powered by its proprietary XingShi Large Language Model (搜索) (XS LLM), was named to the 2026 Fortune China Best Designs list.
The recognition highlights the platform's innovation, real-world implementation, industry value, and social impact in chronic disease management.
Fangzhou reported H1 2026 revenue of RMB1.82 billion, up 22.2% year-over-year, with cumulative registered users exceeding 59.8 million and 282,000 registered physicians.
Fangzhou Inc. (搜索) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, announced that its "AI + Chronic Care" platform has been named to the 2026 Fortune China Best Designs list, recognizing the company's innovation and application of artificial intelligence in chronic disease management.
Now in its fifth year, Fortune China's Best Designs list evaluates projects across innovation, real-world implementation, industry value, and broader social impact. The 2026 list places a particular focus on artificial intelligence, recognizing projects that apply innovation to address industry challenges while demonstrating commercial potential and social value. Fangzhou's inclusion highlights the practicality, scalability, and commercial viability of its AI-powered chronic care model.
Addressing Structural Challenges in Chronic Disease Management
Chronic disease management remains a critical pillar of China's public healthcare system, yet traditional models face persistent challenges, including fragmented services, high labor costs, inconsistent patient follow-ups, and limited personalization. To address these structural constraints and long-term care needs, Fangzhou began exploring AI applications in healthcare as early as 2022.
In 2025, powered by its proprietary "XingShi" Large Language Model (XS LLM), the company launched its "AI + Chronic Care" service model. By embedding AI functionality across the entire patient journey—including health monitoring, medication guidance, follow-up management, and health education—the platform connects fragmented services into a more seamless and personalized care experience.
Tangible Benefits Across Patient and Physician Workflows
As the company scaled its deployment of XS LLM in 2026, the model delivered measurable benefits across both patient and physician workflows. In terms of workflow optimization, the platform streamlines service delivery across physician and patient touchpoints by automating routine tasks and processes to enhance operational efficiency. In terms of enhanced care quality and patient adherence, it integrates professional clinical guidance into everyday health management, empowering individuals to build healthier routines and manage chronic conditions more effectively.
Financial Momentum and Network Expansion
Fangzhou's AI-driven strategy is translating into commercial growth. For the six months ended June 30, 2026, the company reported revenue of RMB1.82 billion, up 22.2% year-over-year from RMB1.49 billion in the first half of 2025. Adjusted net profit increased 6.4% to RMB18.7 million from RMB17.58 million in the prior-year period.
The company's user base continued to expand, with cumulative registered users exceeding 59.8 million. Average monthly active users increased 23.1% to 14.7 million, while registered physicians reached 282,000. Fangzhou's supply-chain network included more than 1,800 suppliers and 1,000 pharmaceutical companies, with prescription medicines accounting for 83.1% of GMV.
AI Integration Across the Healthcare Ecosystem
Beyond patient-facing services, Fangzhou continued expanding applications powered by XS LLM across physician support and internal operations. For physicians, the company integrated AI-powered pre-consultation, clinical support, and academic-assistance capabilities designed to reduce repetitive administrative work and improve post-consultation patient management. AI tools were also deployed across service fulfillment, inventory management, and logistics to enhance operational and supply-chain efficiency.
The company said these initiatives are helping shift chronic disease management from episodic interactions toward continuous, full-cycle healthcare services, while enabling limited physician resources to serve a broader patient population.
Strategic Partnerships and Second-Half Outlook
Fangzhou expanded its pharmaceutical partnerships during the first half, signing strategic agreements with companies including Youcare Pharmaceutical (搜索) and Tenry Pharma (搜索) to extend services into innovative therapies and specialty care. The company also completed agreements and system integration for medical insurance services across Guangdong Province, expanding access to online follow-up consultations, prescription renewals, and medication purchases for insured patients.
Looking ahead, Fangzhou plans to position itself as a "full-lifecycle personal service partner," building an integrated ecosystem serving patients, physicians, and pharmaceutical companies. The company plans to further upgrade its large-model and AI-agent capabilities, scale AI applications, and deepen partnerships with pharmaceutical companies. It expects these initiatives to support its long-term growth while contributing to China's broader Healthy China 2030 objectives.